LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5438 | 5418 | 1.0035 | 1.0059 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5449 | 5752 | 0.9473 | 0.9100 |
| SK-BR-3 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5032 | 5418 | 0.9282 | 0.8663 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5540 | 5752 | 0.9631 | 0.9370 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5032 | 5418 | 0.9284 | 0.8673 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5011 | 5752 | 0.8712 | 0.7788 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4602 | 5418 | 0.8486 | 0.7180 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4214 | 5752 | 0.7327 | 0.5355 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3257 | 5418 | 0.6005 | 0.2516 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 2543 | 2540 | 5752 | 0.4416 | -0.0012 |
| SK-BR-3 | Dasatinib | 10 | uM | LJP6 | 72 | hr | 2543 | 1353 | 5418 | 0.2492 | -0.4407 |
| SK-BR-3 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 1796 | 5752 | 0.3122 | -0.2563 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1972 | 5752 | 0.3429 | -0.1943 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1987 | 5752 | 0.3455 | -0.1890 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2014 | 5752 | 0.3501 | -0.1800 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1973 | 5752 | 0.3430 | -0.1941 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 72 | hr | 2543 | 2168 | 5752 | 0.3769 | -0.1269 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5620 | 5418 | 1.0363 | 1.0637 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5504 | 5418 | 1.0155 | 1.0271 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5369 | 5418 | 0.9897 | 0.9775 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5523 | 5418 | 1.0188 | 1.0331 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5619 | 5418 | 1.0361 | 1.0631 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 72 | hr | 2543 | 5265 | 5418 | 0.9706 | 0.9430 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5710 | 5418 | 1.0543 | 1.1001 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4515 | 5418 | 0.8333 | 0.6917 |